Evotec SE (EVO) stock

EVONasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as EVOTF

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 8, 2026Score 4/30

$1.66−0.03 (-1.78%)

Close on Nov 12, 2026Market cap $590.23MP/E –Yield –

Evotec gross margin

Gross margin is gross profit as a percentage of revenue.

For fiscal 2025 it was 14.5%, against 14.4% the year before. The highest annual figure on record is 29.8% in fiscal 2019.

Period	Period end	Value	Change (pts)
FY2025	Dec 31, 2025	14.5%	+0.1
FY2024	Dec 31, 2024	14.4%	−8.0
FY2023	Dec 31, 2023	22.4%	−0.8
FY2022	Dec 31, 2022	23.2%	−1.4
FY2021	Dec 31, 2021	24.5%	−0.6
FY2020	Dec 31, 2020	25.1%	−4.7
FY2019	Dec 31, 2019	29.8%	–

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is EVO.

Revenue growth-1.1% · median 15.8%

Operating margin-7.1% · median -64.0%

Advertisement
300 × 250

See a number that looks wrong?